Goal Guide

Best Peptides for Longevity in 2025

Evidence-based rankings for healthspan extension, cellular health, and longevity optimization.

Medical Disclaimer: This content is for educational purposes only. Peptides discussed may be research compounds not approved for human use. Consult a healthcare provider before starting any protocol. Full disclaimer →

The Science

Longevity science has identified several key hallmarks of aging that are amenable to peptide intervention: telomere attrition, mitochondrial dysfunction, cellular senescence, loss of proteostasis, and deregulated nutrient sensing. The most promising longevity peptides address multiple hallmarks simultaneously. Epithalon targets telomere maintenance. SS-31 addresses mitochondrial dysfunction. MOTS-c activates AMPK, the master metabolic regulator. Together, these peptides represent a multi-target approach to slowing the biological aging process.

Top Peptides for Longevity

1

Epithalon

Moderate Preclinical / Emerging Human
94/100

The most targeted longevity peptide, directly addressing telomere shortening. 30+ years of Russian research with animal lifespan extension data.

Dosage5–10 mg/day for 10–20 days (cycled)
AdministrationSubcutaneous injection
2

Sermorelin

Strong Human Clinical
85/100

Restores the GH/IGF-1 axis, which is a key driver of age-related decline in muscle mass, body composition, and energy.

Dosage200–300 mcg before bed
AdministrationSubcutaneous injection (prescription)

Free Personalized Analysis

Which peptide matches your biology?

Take the 5-minute PeptidePilot quiz to get a personalized recommendation based on your goals, body, and lifestyle.

How We Compare These Peptides

Telomere supportMitochondrial functionGH axis restorationInflammation reductionEvidence level

✓ Who Should Consider These Peptides

Adults aged 40+ with a strong interest in longevity optimization, those with a family history of age-related disease, and individuals seeking to maintain healthspan alongside lifespan.

✗ Who Should Avoid These Peptides

Individuals with active cancer. Those under 35 whose natural aging mechanisms are not yet significantly compromised.

Frequently Asked Questions

Explore Other Goals